NEW YORK (GenomeWeb) – Sequenom said after the close of the market Friday that it has sold its bioscience business, which includes its MassArray system, to Agena Bioscience for $31.8 million.

Sequenom had said in September that it would conduct a strategic review for the business, formerly called the Genetic Analysis segment, but at the time didn't offer details on the reason for seeking a potential sell off.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.